Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 aged or over~* Patients with blood pressure measured at Visit 1; MSSBP≤180mmHg and MSDBP≤110 mmHg if on anti-hypertensive drugs, 160mmHg≤MSSBP≤199mmHg and 80mmHg≤MSDBP≤119mmHg if not on anti-hypertensive drugs~* Patients with blood pressure measured at Visit 2 were 160mmHg≤MSSBP≤199mmHg and 80mmHg≤MSDBP≤119mmHg~Exclusion Criteria:~* Inability to stop all prior anti-hypertensive drugs safely during wash out period of 3 to 7 days~* ≥ sitSBP 20mmHg or ≥ sitDBP 10mmHg of variation in three measurements from the reference arm selected at Screening~* History of hypersensitivity to dihydropyridines, angiotensin II receptor blockers or thiazide diuretics~* Secondary hypertension or suspected to be~* Continuously took medicinal drugs that might affect blood pressure rather than anti-hypertensive drugs more than 3 months~* Type 2 diabetes mellitus which is not controlled or with type 1 diabetes mellitus~* History of severe neurovascular disease, severe heart disease~* Known as moderate or malignant retinopathy.~* Renal diseases; serum creatinine ≥ 2mg/dl~* Hepatic diseases; increase in ALT or AST ≥ 2xUNL~* Anuria~* Hyponatremia/hypokalemia or hypercalcemia~* Active Gout~* Surgical or medical diseases which might significantly change ADME of medicines~* History of malignant tumor~* Autoimmune diseases~* History of alcohol or drug abuse~* Positive to pregnancy test, nursing mother, woman with an intention of pregnancy~* Considered inappropriate to participate in the clinical trial with any reason, based on investigator's decision~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amlodipine/losartan (Type: EXPERIMENTAL): None
- amlodipine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).